Cover Page



Universiteit Leiden



The handle <u>http://hdl.handle.net/1887/29964</u> holds various files of this Leiden University dissertation.

Author: Verbiest, Marjolein Elisabeth Anna Title: The implementation of smoking cessation care in general practice Issue Date: 2014-12-02



















6

An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: Population based study

Marjolein E.A. Verbiest¹, Niels H. Chavannes¹, Mathilde R. Crone¹, Mark N. Nielen², Dewi Segaar³, Joke Korevaar², & Willem J.J. Assendelft^{1,4} (2013)

- ¹ Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands
- ² Netherlands Institute for Health Services Research, Utrecht, the Netherlands
- ³ STIVORO, Dutch Expert Centre on Tobacco Control, the Hague, the Netherlands
- ⁴ Department Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Addiction, 108(12), 2183-2192

ABSTRACT

2

3 Aims

4 To examine the impact of two national tobacco control interventions in the past

- 5 decade on (dispensed) prescriptions of stop-smoking medication.
- 6

7 Design

8 Ecological study with interrupted time-series analyses of quarterly data points

- 9 of three nationwide representative databases.
- 10

1 Setting

The Netherlands 2001-2012, with the introduction of the guideline for smoking
cessation care in general practice (GP) in 2007 and full insurance coverage for
smoking cessation treatment in 2011.

15

16 Participants

17 GPs, pharmacists and persons in the general population aged 15 years and older.

18

19 Measurements

Time-series plots were visually inspected and segmented regression analyses
were performed to estimate the change in level and slope of (dispensed) prescriptions of stop-smoking medication and smoking prevalence in the years
preceding and after the tobacco control interventions.

24

25 Findings

No measurable effects of the GP guideline on (dispensed) prescriptions were observed. Shortly after the start of health insurance coverage, an estimated increase in primary care prescriptions of 6.3 per 1.000 smokers (95% CI 2.9-9.8; p=0.001) and 17.3 dispensed items per 1.000 smokers (95% CI 12.5-22.0; p<0.000) was accompanied by a sudden drop in smoking prevalence of 2.9% (95% CI 4.6-1.1; p=0.002) in the first quarter of 2011. Immediately after the coverage abolition, smoking prevalence increased by 1.2% (95% CI 0.5-2.8; p=0.156) and dispensed prescription rates decreased with 21.6 per 1.000 smokers (95% CI 26.0-17.2; p<0.000).

35

36 Conclusions

37 Full health insurance coverage for smoking cessation treatment in the Nether-

- 38 lands was accompanied by a significant increase in the number of (dispensed)
- 39 prescriptions of stop-smoking medication and a decrease in smoking prevalence.

INTRODUCTION

2

In the past decade, cigarette consumption has declined in various high and middle-income countries.¹ However, about 25% of the Dutch adult population still smokes.² As a result, in the Netherlands, the attributive risk of smokingrelated mortality is estimated at 21% which is relatively high compared to 16% in Europe and 12% worldwide.^{3;4} Consequently, 13% of the Dutch disease burden and an annual 2 billion euros in healthcare costs are attributed to the use of tobacco.^{5;6}

Therefore, in the last decade multiple national tobacco control interventions were implemented.^{7;8} The Dutch government initiated several policies aimed at reducing exposure to environmental tobacco smoke and discouraging tobacco use. Bans on tobacco advertisement (November 2002) and the sale of tobacco to minors (January 2003) were implemented, and legislation was introduced for smoke-free workplaces (January 2004) and public places (April 2006 and July 2008). In addition, national guidelines for smoking cessation support in health care were developed and implemented. Moreover, in the year 2011, full health insurance coverage for evidence-based pharmacotherapy in combination with behavioural counseling was implemented.

These tobacco control interventions are likely to reduce smoking initiation, increase the number of quit attempts and/or use of effective treatments and therefore reduce smoking prevalence.⁹⁻¹⁶ For example, in the Netherlands, smoking prevalence decreased from 30.1% in 2001 to 25.9% in 2012.² However, the impact of national tobacco control interventions on primary care prescriptions of stop-smoking medication is not yet clear.

GPs are more likely to deliver successful smoking cessation treatment when they use a systematic approach and when structural barriers (e.g. lack of financial reimbursement) are alleviated.^{17,18} Therefore, we examined the impact of two national tobacco control interventions on prescriptions of stop-smoking medication in general practice that were likely to have directly prompted GPs to support smokers to quit. These two interventions are the guideline for smoking cessation care introduced in general practice and the full health insurance coverage period of stop-smoking treatment.

- 34
- 35
- 36
- 37
- 38
- 39

1 METHODS

2

3 Design

To explore the hypotheses, we used an ecological study design in which the unit of analysis was the population rather than the individual. The main advantage of this type of study is the presence of available data which enabled a relatively fast and inexpensive study. However, the results cannot be extrapolated to the individual level and no confounder data were available. Moreover, inferences regarding causality need to be made with caution, taking into account other explanations for changes in outcomes. Nevertheless, this type of study is useful to generate new hypotheses based on the results.

12

13 National tobacco control interventions

We assessed the impact of potentially high-impact national tobacco control interventions on prescriptions of stop-smoking medication in general practice, i.e. i) the introduction of the GP guideline for smoking cessation care, ii) full health insurance coverage of evidence-based pharmaceuticals and behavioural treatment for smoking cessation.

Implementation of the first Dutch guideline 'Treatment of Tobacco Dependence' started in 2004, accompanied by campaigns in which physicians and other healthcare providers were informed about the guideline and were provided with additional insight into the addictive character of smoking.¹⁹ This implementation period resulted in the first version of a guideline for treatment of tobacco use in general practice, developed by the Dutch College of General 24 Practitioners in June 2007.²⁰ This guideline recommends actively enquiring about a patient's motivation for stopping smoking. When a patient smokes more than 10 cigarettes/day and is motivated to quit, the first choice recommendation is to prescribe nicotine replacement therapy (NRT) in combination with behavioural treatment. If specifically requested by the patient, or in case of relapse after NRT, the antidepressant smoking cessation agents bupropion and nortriptyline are recommended. In December 2006 varenicline was introduced in the Netherlands and (after an evaluation period) was incorporated into the GP guideline in March 2011.21

In January 2011, the Dutch government introduced full health insurance coverage for evidence-based smoking cessation programs using pharmacotherapy in combination with behavioural counseling. Due to governmental changes, a shift of focus of the Ministry of Health on people's autonomy regarding lifestyle choices and overall cutting in budget led to the cancellation of full health insurance coverage after only one year. As a result, only behavioural support and not

GP prescriptions of stop-smoking medication **155**

1 pharmacological support for smoking cessation was reimbursed during the year

2 2012.

We analysed the effects of both policies within the same regression model

4 which allowed us to quantify the effects of one policy taking into account the

5 effect of the other policy.

6

7 Data extraction

For a full overview of the number of primary care prescriptions of stop-smoking pharmaceuticals in the past decade we used two nationwide representative databases of i) prescribed medication in general practice and ii) prescriptions dispensed in outpatient pharmacies. The term 'prescription' refers to an order of the GP for the pharmacist to dispense and the patient to take the medication. The act of dispensing is defined as providing a patient with their labelled medication. In the Netherlands all stop-smoking medications are prescription drugs, with the exception of NRT which is also available over-the-counter. At quarterly intervals, we extracted data on prescriptions and dispensed items

of stop-smoking medication in general practices and pharmacies. Data on nortriptyline were excluded because this pharmaceutical is also used for various
other indications. Finally, to explore the impact of the tobacco control interventions on smoking prevalence a third database was used (see C. below).

- The privacy regulation of the study was registered at the Dutch Data Protection Authority. According to current Dutch legislation, neither informed consent nor approval is required from a medical ethics committee for observational studies using anonymized data records.²²
- 25

A. The number of quarterly prescribed stop-smoking medication in general practice was derived from the Netherlands Information Network of Primary Care (LINH) in the period 2001-2011. Data were retrieved from electronic medical patient records, kept in a representative sample of 84 general practices with approximately 350,000 listed patients. The characteristics of the study population (GPs and patients) are comparable with the general Dutch population in terms of age and gender.²³ We selected prescriptions of NRT, varenicline and bupropion in the period 2001-2011 and calculated prescription rates per 1,000 smokers. These rates were calculated by dividing the absolute number of primary care prescriptions by the number of smokers, multiplied by 1,000. The number of smokers was based on the total population²⁴ and smoking prevalence.²⁵ In this database it was not possible to differentiate between prescriptions of bupropion as an anti-depressant or for smoking cessation.

39

156 Chapter 6

B. For prescriptions of stop-smoking medication dispensed in outpatient pharmacies, we used quarterly data of the Dutch Foundation for Pharmaceutical
Statistics (SFK) in the period 2001-2012. The SFK gathers data from a representative panel of 95% of Dutch community pharmacies. Data were extrapolated to nationwide figures. We selected dispensations of NRT, varenicline
and bupropion in the period 2001-2012 and calculated dispensed rates per
1,000 smokers.

8

C. We used quarterly data from the Dutch Continuous Survey of Smoking Habits
(DCSSH) from 2001-2012 for smoking prevalence. The DCSSH assesses smoking behaviour of the Dutch adult population (15 years and older). The DCSSH
has been part of the CASI omnibus (Computer-Assisted Self-Interviewing) of
TNS NIPO from 2001-2008. From 2009 onwards, the DCSSH has been performing an ad-hoc internet survey in which a representative sample of about 350
subjects is selected from a database of 200,000 respondents every week. Up
to 2008, the data of the DCSSH were weighted on the basis of respondents'
gender, age and education level, the province in which they lived, and their
family and community size. Since January 2009, the data are also weighed on
the basis of respondents' social economic status. Smoking prevalence was
assessed by asking participants 'Do you (ever) smoke?'

21

22 Statistical methods

We drew and visually inspected time-series plots to detect marked changes in the number of (dispensed) prescriptions, and smoking prevalence in the past decade. Interrupted time-series analyses (SPSS 20.0) were used to evaluate the impact of the national tobacco control interventions on (dispensed) prescriptions of stop-smoking medications and smoking prevalence.²⁶ The advantages of these analyses are the fact that they allowed us to assess whether the interventions changed the outcomes immediately as well as over a period of time, taken into account pre-existing trends in the data.²⁶⁻²⁸ Prior studies have shown that segmented regression analysis is a suitable method for analysing interrupted time-series data in order to assess the impact of extraneous events on smokingrelated outcomes.^{26;29-32} We examined the following linear regression equation:

35 $Y_t = B_0 + B_1^* time_t + B_2^* intervention1_t + B_3^* time after intervention1_t + B_4^* intervention2_t$ 36 $+ B_5^* intervention3_t + e_t$

37

Time (in quarters) was included as a continuous predictor. Intervention indicatedthe introduction of the GP guideline, and the introduction and abolition of health

insurance coverage of stop-smoking treatment; pre-intervention time points
 were coded 0 and post-intervention time points were coded 1. *Time after inter- vention* was coded 0 up to the last time point before the intervention, and was
 sequentially coded from 1 thereafter.

In the model, Y_t represents the outcome variable at time t (the number of (dispensed) prescriptions per 1,000 smokers or smoking prevalence). B₀ estimates the baseline level/intercept of the outcome at time point zero; B₁ estimates the quarterly change in outcome prior to the interventions; B₂ (introduction GP-guideline), B₄ (introduction insurance coverage), and B₅ (abolition insurance coverage) estimates the change in level immediately after the interventions; and B₃ estimates the change in slope after the introduction of the GP-guideline compared with the slope before the intervention. We assessed both full and parsimonious models in which we incorporated all parameters regardless of their significance and only significant covariates, respectively.

We did not assess the impact of the GP guideline introduction on the number of (dispensed) prescriptions of varenicline because this pharmaceutical was introduced in the Netherlands around the same time as the GP guideline (December 2006). Furthermore, we only assessed the immediate effect of the introduction and abolition of the insurance coverage in (dispensed) prescriptions and smoking prevalence, since we lacked sufficient time-points to estimate a change in trend.

Since time is a predictor in segmented regression analyses, it is likely that consecutive observations are correlated, which is called autocorrelation. Since regression analysis assumes independency between observations and autocorrelation can overestimate or underestimate significance, we examined autocorrelation by visually inspecting residual plots. Autocorrelation was judged to be present if there were statistically significant spikes in the correlogram. In addition, the Durbin-Watson statistic was used to test serial autocorrelation; based on the number of observations and regressors in the model we determined an upper and lower bound and tested the null hypothesis of zero autocorrelation in the data.³³ We found first-order autocorrelation in the time-series of the total prescription rate, prescription rate of NVM, and of the number of (dispensed) prescription of bupropion and varenicline. These time-series were differenced by subtracting the value of an earlier observation from the value of a later observation in order to control for autocorrelation.^{26;28} The regression models were re-checked after time-series were differenced in order to confirm that autocorrelation was accounted for

- 38
- 39

RESULTS

2

Figure 1 shows the time-series plots of primary care prescriptions of stopsmoking medication and dispensed items in pharmacies in the past decade. 4 It highlights the introduction of the smoking cessation guideline in general practice and the period of the full health insurance coverage of smoking cessation treatment. Both time-series were relatively low in the period 2001-2006, but show a small increase after 2007. Next, both time series increased steeply in 8 2011, especially in the first and last quarter. Thereafter, dispensed prescriptions in pharmacies show a decrease in 2012. Overall, the number of stop-smoking medication prescribed in general practices is lower than dispensed in pharmacies. This can probably be explained by other clinical specialists also prescribing these pharmaceuticals. Further explanations are that GPs sometimes prescribe multiple doses of stop-smoking medications at the same time, and pharmacists 14 sometimes dispense the labelled medication at multiple moments to be able to check for possible side-effects.³⁴

Figure 2 shows the number of primary care prescriptions and dispensed items of NRT, varenicline, and bupropion. Visual inspection points out that between 2001-2008, the number of primary care prescriptions of NRT increased in the first quarter of every year, which can be defined as seasonality in the time-series. In this period, the prescription rates of NRT show little change, with a single small increase in 2008. Both time-series of NRT show a steep increase in 2011, especially in the first and last quarter.

After the introduction of varenicline in December 2006, visual inspection of figure 2 shows that both prescriptions and dispensed items of this pharmaceutical rapidly increased, particularly in the first and last quarter of 2011. Next, dispensed items of varenicline show a steep decrease in 2012.

With regard to bupropion, we observed a discrepancy between primary care prescriptions and dispensed items from 2007 (Figure 2). At that time, bupropion was registered in the Netherlands as an anti-depressant in addition to stop-smoking medication.³⁵ The observed discrepancy can be explained by the fact that the primary care prescriptions in this study represent the total number of prescriptions for both depression and quit smoking and the dispensed items represent only stopsmoking medication. Both prescriptions and dispensed items of bupropion show a single slight increase in 2004. Subsequently, primary care prescriptions of bupropion increase in 2011 and the number of dispensed items show a slight decrease in 2012.

- 20
- 39







Figure 2. The number of primary care prescriptions and dispensed prescriptions of nicotine replacement therapy, varenicline, and bupropion per 1.000 smokers in the period 2001-2012

1 GP guideline

2 When accounting for the effect of the introduction of the health insurance

 $_3$ $\,$ coverage, there was no statistically significant immediate (B_2) and long-term (B_3) $\,$

4 effect of the introduction of the GP guideline on the number of primary care

- 5 prescriptions and dispensed items (Table 1).
- 6

7 Health insurance coverage

According to the segmented regression analysis, the total number of stop-9 smoking medication prescribed in general practices and dispensed in pharma-10 cies showed a significant increase in 2011, the year in which smoking cessation 11 treatment was reimbursed (Table 1). In the first quarter of 2011, prescriptions 12 and dispensed items increased by 6.3 per 1.000 smokers (95% CI: 2.0-9.8; p =0.001) and 17.3 per 1.000 smokers (95% CI:12.5-22.0; p = <0.000), respectively 14 (Table 2). This change also occurred in the number of primary care prescriptions 15 and dispensed items of NRT and varenicline (Table 1). Subsequently, a significant 16 decrease in the number of dispensed items of stop-smoking medication was 17 established of 21.6 items per 1.000 smokers (95% CI: -25.9 - -17.2; p <0.000) in the 18 first quarter of 2012, immediately after the abolition of the coverage. This effect 19 also occurred in the number of dispensed items of varenicline and NRT.

20

21 Smoking prevalence

Visual inspection of figure 1 shows a steady overall decline in smoking prevalence
in the period 2001-2012, with a more prominent decrease in 2004, 2007 and 2011.
Thereafter, smoking prevalence shows a marked increase in 2012. Segmented
regression analyses confirmed a significant decrease in the first quarter of 2011,
immediately after the introduction of the health insurance coverage (Table 1).

27

DISCUSSION

30

In the past decade, the number of primary care prescriptions of stop-smoking
medication in general practices and dispensed items in pharmacies increased.
We found a significant change in (dispensed) prescriptions following full health
insurance coverage of stop-smoking support in the year 2011. Moreover, our data
suggest a positive impact of this tobacco control policy on smoking prevalence.
We did not find measurable effects of the introduction of a guideline for smoking
cessation care in general practice on prescription rates.

-
- 39

	Pre G	P guideline	and	Post iı	ntroduction G	P guide	line			Post ir	troduction of		Post ab	olition of insur	ance
	insur	ance covera	ge period	for sn	oking cessat	ion care				insura	ince coverage		coverag	ge	
Prescriptions	B1	95% CI	d	\mathbf{B}_2	95% CI	р	\mathbf{B}_3	(95% CI)	d	\mathbf{B}_4	95% CI	d	B5	95% CI	d
Total ^a	0.02	-0.09 - 1.14	0.676	0.84	-2.04 - 3.71	0.560	-0.10	-0.40 - 0.20	0.499	6.31	2.86 – 9.76	0.001	.	1	
Bupropion	0.02	-0.03 - 0.07	0.374	0.12	-1.13 - 1.37	0.845	-0.05	-0.18 - 0.08	0.475	0.91	-0.59 - 2.41	0.227	,	ı	
NRT	-0.00	-0.03 - 0.02	0.832	0.11	-0.52 - 0.73	0.735	-0.00	-0.07 - 0.07	0.986	1.97	1.23 – 2.72	<0.000	,		
Varenicline	0.01	-0.03 - 0.05	0.644						ı	2.97	1.30 - 4.64	0.001	,	ı	
Dispensed iten	IS														
Total ^a	-0.01	-0.16 - 0.15	0.924	2.68	-1.23 – 6.59	0.173	0.39	-0.02 - 0.79	0.060	17.26	12.53 - 21.98	<0.000	-21.56	-25.9317.19	<0.000
Bupropion	0.03	-0.03 - 0.08	0.292	-0.31	-1.64 - 1.03	0.645	-0.02	-1.28 - 1.92	0.688	0.32	-1.28 - 1.92	0.688	-0.79	-2.27 – 0.69	0.288
NRT	0.06	0.01 - 0.11	0.026	0.20	-1.15 - 1.55	0.768	0.01	-0.13 - 0.15	0.929	5.45	3.82 – 7.08	<0.000	-5.86	-7.37 – -4.35	<0.000
Varenicline	0.02	-0.07 - 0.12	0.618						ı	4.72	0.65 – 8.79	0.024	-11.30	-16.056.55	<0.000
Smoking prevalence	-0.14	-0.20 – 0.09	<0.000	-0.15	-1.60 - 1.30	0.835	0.17	0.02 – 0.32	0.028	-2.86	-4.61 – -1.11	0.002	1.16	-0.46 – 2.79	0.156
Parameters in pensed) prescr sation treatme of the GP guidé GP guideline; E health insuran	the full iptions J nt; B2: ch line; B3: 4: chang ce cover	segmented ber 1.000 sm nange in the change in tr change in tr e in the qua age for smo	regressio: toker and e quarterly rend in qu irterly lew sking cess	n mode smokir y level (arterly el of (di ation ti	al are reporte 1g prevalence of (dispensed number of (d spensed) pres reatment; B ₅ :	d (parsi (%) pric (%) prescr) prescr ispense ispense change	monio or to the iptions d) pres ns per (in qua	us model sh e introductic per 1.000 sr criptions pei criptions pei urterly level o	owed co on of the nokers a r 1.000 si r and sm r and sm	mparah GP guic nd smc moker a toking p insed) p	ole effects). B. deline and the oking prevaler and smoking r prevalence (%) prescriptions I	: quarter : health ii ice (%) im orevalenc immedii immedii oer 1.000	ly chang nsurance nmediate e (%) afte ately afte smoker	je in the numb e period for smo ely after the int er the introduct er the introduct and smoking r	er of (dis- bking ces- roduction ion of the ion of the revalence

NRT: nicotine replacement therapy; CI: confidence interval ^aTotal number of (dispensed) prescriptions consist of bupropion, NRT, and varenicline

1 Current results compared to previous research

These results complement other Dutch reports indicating an upward trend in the use of pharmacological aids for smoking cessation in recent years.³⁶ Nevertheless, relatively few stop-smoking prescriptions are actively suggested by GPs and guide-lines for cessation support are often implemented suboptimal in general practice.^{16;37;38} Moreover, these guidelines also comprise behavioural cessation support, which we did not addressed in our study, which may explain why we did not found effects of the introduction of the GP guideline introduction on prescription rates. Regarding our findings related to the effect of full health insurance coverage on prescription rates and smoking prevalence, latest research also shows a strong association between this policy and a more than ten-fold increase in telephone counseling for smoking cessation.³⁹ Moreover, a recent review of 11 randomized controlled trials of four countries found a positive effect of full health insurance

15

5 Strengths and weaknesses

A strength of our study is that three large nationwide representative databases were used with regard to prescriptions in general practice, dispensed items in pharmacies and smoking prevalence. With regard to the SFK database, in 2011 an unknown and possibly substantial part of Dutch health insurance companies covered dispensed prescriptions of stop-smoking medications only of specific (online) pharmacies; therefore, the precise number of dispensed items was unknown in this year. This implies that these data might underestimate the actual situation and that the impact of health insurance coverage might be even larger. Another strength of the study is the fact that in the Dutch healthcare system, almost all non-institutionalized Dutch citizens are registered with a general practice, which resulted in data with strong external validity.

Regarding the analyses, we assessed the impact of tobacco control interventions with quarterly data points, which enables us to detect subtle temporary effects in the period prior to or immediately after the interventions. Additionally, we included the most recent available data in order to analyse changes in trends following the abolition of the health insurance coverage.

However, some limitations of the study have to be mentioned. First, it was not possible to differentiate between bupropion prescriptions for treating depression and those used as a quit-smoking aid in general practice. Furthermore, we did not include data regarding NRT distributed over-the-counter. Because the estimated mean costs of NRT are 2.57 Euro per day⁴⁰, this may have been an incentive for patients to get a prescription of the GP during the period smoking cessation aids were reimbursed. For this reason, it is possible that the reported

164 Chapter 6

large increase in the number of (dispensed) prescriptions of NRT in the period
 2011-2012 is partially caused by the fact that over-the-counter distribution of
 these aids are not included into the analyses in the pre-intervention period.

With regard to the segmented regression analyses, when assessing the impact 4 of an intervention on time series, the impact of extraneous events on the observed changes in the series must be taken into account.²⁹ In the past decade, multiple tobacco control policies have been implemented in the Netherlands which might 7 have had an (indirect) effect on the number of prescriptions; for example, tax 8 increases, and smoke-free legislation in the workplace (2004) and other public areas (2008). However, in 2011 no other tobacco control measures were introduced in the Netherlands. Although caution is required in assuming causal relations, it seems likely that the increase in (dispensed) prescriptions and decrease in smoking prevalence in 2011 can be attributed to the introduction of the health insurance coverage. This assumption is supported by the fact that we visually detected 14 a marked increase in smoking prevalence and statistically confirmed a decrease in dispensed items immediately after the abolition of the coverage.

17

18 Conclusion and practical implications

The results of this study suggest that health insurance coverage for smoking cessation treatment prompt GPs to prescribe evidence-based pharmaceuticals for smoking cessation and have positive effects on smoking prevalence. Therefore, these results are a relevant addition to the existing evidence demonstrating the importance of tobacco control policies in the effective tackling of the tobacco epidemic.^{10-15;29;41;42}

We argue that policy makers and the tobacco-control community consider this evidence in developing future tobacco control policy. Given the limitations of our study, we recommend replication of population based studies to further evaluate the effectiveness of tobacco control interventions.

- 29 30 31 32 33 34 35 36 37
- 20

1 REFERENCES

- World Health Organization. Tobacco Fact Sheet. 2011. Available from: http://www.
 wpro.who.int/mediacentre/factsheets/fs_201203_tobacco/en/index.html.
- 2. STIVORO. Dutch key figures of smoking in 2011. An overview of recent Dutch data regarding smoking behaviour 2012. The Hague, the Netherlands, STIVORO.
- World Health Organization. WHO global report: Mortality attributable to tobacco 2012. Geneva, Switzerland, World Health Organization. Available from: http://www. who.int/tobacco/publications/surveillance/rep_mortality_attributable/en/.
- Nagelhout GE. Summary of the World Health Organization Global Report: Mortality
 Attributable to Tobacco. 2012. The Hague, the Netherlands, STIVORO. Available from: http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/gezondheidsschade/Samenvatting%20WHO %20Report%20Mortality%20Attributable%20to%20Tobacco.pdf.
- 5. Statistics Netherlands. Statistics Causes of Death. 2011. Available from: http:// statline.cbs.nl/StatWeb/ publication/?VW=T&DM=SLNL&PA=7233&HD=130716-1139&HDR=T&STB=G1,G2,G3.
- Nagelhout GE. Summary WHO Global Report: Mortality Attributable to Tobacco.
 2012. The Hague, the Netherlands, STIVORO. Available at: http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/gezondheidsschade/Samenvatting%20WHO %20Report%20Mortality%20Attributable%20to%20 Tobacco.pdf.
- 7. World Health Organization. WHO Report on the Global Tobacco Epidemic. MPOWER: six policies to reverse the tobacco epidemic. 2008. Geneva, Switzerland, World Health Organization. Available from: http://www.who.int/tobacco/mpower/facts_findings/ en/index.html.
- 8. World Health Organization. Key facts and findings related to the MPOWER package.
 2012. Geneva, Switzerland, WHO Tobacco Free Initiatives. Available from: http:// www.who.int/tobacco/mpower/mpower_report_six_policies_2008.pdf.
- Boyle RG, Solberg LI, Magnan S, Davidson G, Alesci NL. Does Insurance Coverage for Drug Therapy Affect Smoking Cessation? Health Affairs 2002; 21(6):162-168.
- 10. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking
 cessation treatment may double the abstinence rate: results of a randomized trial.
 Addiction 2005; 100(7):1012-1020.
- 11. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction 2006; 101(11):1656-1661.
- Nagelhout GE, Willemsen MC, de VH. The population impact of smoke-free work place and hospitality industry legislation on smoking behaviour. Findings from a
 national population survey. Addiction 2011; 106(4):816-823.
- Nagelhout GE, de VH, Fong GT, Candel MJ, Thrasher JF, van den Putte B et al. Pathways of Change Explaining the Effect of Smoke-Free Legislation on Smoking Cessation in the Netherlands. An Application of the International Tobacco Control Conceptual Model. Nicotine & Tobacco Research 2012;1-9.
- Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC. The effect of
 tobacco control policies on smoking prevalence and smoking-attributable deaths.
 Findings from the Netherlands SimSmoke Tobacco Control Policy Simulation Model.
 Addiction 2012; 107(2):407-416.

166 Chapter 6

- Nagelhout GE, de VH, Boudreau C, Allwright S, McNeill A, van den Putte B et al. Comparative impact of smoke-free legislation on smoking cessation in three European countries. Eur J Public Health 2012; 22(1):4-9.
- Wilson A, Sinfield P, Rodgers S, Hammersley V, Coleman T. Drugs to support smoking cessation in UK general practice: are evidence based guidelines being followed?
 Qual Safety Health C 2006; 15(4):284-288.
- 6 17. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal contact smoking cessation program for Dutch general practitioners: a randomized controlled trial. Prev Med 2001; 32(2):182-190.
- 18. Reda AA, Kotz D, Evers SM, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Systematic Reviews 2012; (2).
- Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Behandeling van Tabaksverslaving [Guideline Treatment of Tobacco Dependence]. Alphen aan den Rijn, the Netherlands: Van Zuiden Communications B.V.; 2009.
- Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al. Dutch College of General Practitioners Guideline for Smoking Cessation. Huisarts Wet 2007; 50(7):306-314.
- Wiersma TJ, Chavannes NH. Addendum NHG-Standaard Stoppen met roken: Varenicline voortaan ook bruikbaar bij stoppen met roken [Addendum Dutch College of general practitioners guideline for smoking cessation: Varenicline hereafter suitable for smoking cessation treatment]. Huisarts & Wetenschap 2011; 54(3):156-157.
- 22. CCMO [Central Committee on Research involving Human Subjects]. The Review System in the Netherlands. 2012. Available at: http://www.ccmo-online.nl/main. asp?pid=1&taal=.
- Stirbu-Wagner I, Dorsman S, Visscher S, Davids R, Gravenstein J, Abrahamse H et
 al. Netherlands LINH databse. Feiten en cijfers over huisartsenzorg in Nederlands
 [Information Network of Primary Care. Facts and Figures on Dutch General Practice]
 2010. Utrecht/Nijmegen: NIVEL/IQ. Available from: http://www.LINH.nl.
- 24. Centraal Bureau voor de Statistiek [Statistics Netherlands]. Bevolking kerncijfers [Population core figures]. 2013. Available from: http://statline.cbs.nl/
 27 StatWeb/publication/?DM =SLNL&PA=37296ned&D1=0,3,10-13&D2=50-63&HDR =G1&STB=T&VW=T.
- 25. STIVORO. Percentage rokers 15 jaar en ouder [Percentage smokers adults 15 years and olders, 2001-2012] 2013. Available from: http://stivoro.nl/wp-content/uploads/persberichten/Bijlage%20 bij%20persbericht %20rookcijfer%202012.pdf.
- Szatkowski LC. Can primary care data be used to evaluate the effectiveness of tobacco control policies? Data quality, method development and assessment of the impact of smokefree legislation using data from The Health Improvement Network. Nottingham, England: The University of Nottingham; 2011.
- Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an
 example to evaluate regionalized perinatal care. Am J Public Health 1981; 71(1):38-46.
- Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27(4):299-309.

39

29. Szatkowski L, Coleman T, McNeill A, Lewis S. The impact of the introduction of 1 smoke-free legislation on prescribing of stop-smoking medications in England. Addiction 2011; 106(10):1827-1834. Langley TE, Huang Y, McNeill A, Coleman T, Szatkowski L, Lewis S. Prescribing of 30. 4 smoking cessation medication in England since the introduction of varenicline. Addiction 2011; 106(7):1319-1324. Federico B, Mackenbach JP, Eikemo TA, Kunst AE. Impact of the 2005 smoke-free 31. policy in Italy on prevalence, cessation and intensity of smoking in the overall popu-7 lation and by educational group. Addiction 2012; 107(9):1677-1686. Bajoga U, Lewis S, McNeill A, Szatkowski L. Does the introduction of comprehensive 32. smoke-free legislation lead to a decrease in population smoking prevalence? Addiction 2011; 106(7):1346-1354. Savin NE, White KJ. The Durbin-Watson test for serial correlation with extreme 33. sample sizes or many regressors. Econometrica 1977; 45(8):1989-1996. Stichting Farmaceutische Kengetallen [Dutch Foundation for Pharmaceutical Statis-34. tics]. Uitgifte van stoppen-met-rokenmedicatie door Nederlandse apotheken in de periode 2011-2012 [Stop smoking medication dispensed in Dutch pharmacies in the period 2011–2012] 2012. Available from: GlaxoSmithKline Receives First European Approval for Wellbutrin XR®. Medical 35. News Today 2007. Available from: http://www.gsk.com/media/press-releases/2007/ glaxosmithkline-receives-first-european-approval-for-wellbutrin-xr.html. de Korte D, Nagelhout GE, Feenstra D, Zeegers T, van der Meer R, Willemsen MC. 36. Hulpmiddelen voor stoppen met roken 1992-2008 [Aids for smoking cessation 1992-2008] 2008. The Hague, the Netherlands, STIVORO. Available from: http://stivoro.nl/ wp-content/uploads/2012/docs/rapporten/ stoppenmetroken/Themapublicatie%20 Hulpmiddelen%20voor%20Stoppen%20met%20Roken%201992%202008.pdf. de Korte D, van Schayck OCP, van Spiegel P, Kaptein AA, Sachs A, Rutten-van Mölken 37. M et al. Supporting smoking cessation in healthcare: obstacles in scientific under-24 standing and tobacco addiction management. Health 2010; 2(11):1272-1279. de Korte D, Nagelhout GE, Willemsen MC. Stoppen-met-rokenadvisering foor Ned-38. erlandse huisartsen 2001-2009 [Smoking cessation advisement in Dutch general practice: 2001-2009] 2010. The Hague, the Netherlands, STIVORO - for a smoke-free future. Available from: http://stivoro.nl/wp-content/uploads /themapublicaties/ stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20 door%20huisartsen%20in%20Nederland%202001%20 2009.pdf. Willemsen MC, Segaar D, van Schayck CP. Population impact of reimbursement for smok-39. ing cessation: A natural experiment in the Netherlands. Addiction 2013; 108: 602-604. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline 40. compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24(1):51-61. Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation 41. aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tobac Control 2007; 16(4):255-260. Kaper J, Wagena EJ, van Schayck CP, Severens JL. Encouraging smokers to quit: the 42. cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006; 24(5):453-464.